{"gene":"CXCL11","run_date":"2026-04-28T17:28:53","timeline":{"discoveries":[{"year":1998,"finding":"CXCL11 (I-TAC) was identified as a novel non-ELR CXC chemokine that binds selectively to CXCR3 with higher affinity than CXCL9 or CXCL10, induces transient intracellular calcium mobilization and chemotactic migration in IL-2-activated T cells and CXCR3-transfected cell lines, but not in neutrophils or monocytes.","method":"Receptor binding assays, calcium flux assays, chemotaxis assays in activated T cells and CXCR3 transfectants","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal functional assays (binding, calcium flux, chemotaxis) with receptor-transfected cells; foundational discovery paper with >600 citations","pmids":["9625760"],"is_preprint":false},{"year":2003,"finding":"CXCL11 binds and activates CXCR3-B, an alternatively spliced variant of CXCR3, which mediates angiostatic (anti-proliferative/pro-apoptotic) effects on endothelial cells, distinct from the pro-survival signaling of CXCR3-A.","method":"HMEC-1 transfection with CXCR3-A or CXCR3-B constructs, radioligand binding, DNA synthesis assays, apoptosis assays, signal transduction analysis","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 — reconstitution in transfected cells with multiple functional readouts; replicated with primary endothelial cultures; >500 citations","pmids":["12782716"],"is_preprint":false},{"year":2000,"finding":"CXCL11, CXCL9, and CXCL10 (CXCR3 agonists) act as natural antagonists for CCR3, competing for eotaxin binding to CCR3-bearing cells and inhibiting CCR3-mediated migration and Ca2+ responses without inducing CCR3 internalization; CXCL11 was the most efficacious antagonist.","method":"Competitive binding assays, calcium flux assays, chemotaxis assays with CCR3 transfectants and human eosinophils; hybrid chemokine construction","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal assays including binding competition, calcium flux, chemotaxis, and structure-function with hybrid chemokine","pmids":["11110785"],"is_preprint":false},{"year":2006,"finding":"CXCL11 (I-TAC) binds with high affinity to CXCR7 (RDC1), an alternate receptor that does not couple to G-proteins or induce calcium mobilization or cell migration, but instead confers cell survival and adhesion advantages; CXCR7 expression promotes in vivo tumor growth.","method":"Radioligand binding, calcium mobilization assays, cell migration assays, adhesion assays, small molecule antagonist studies, in vivo tumor models","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods including binding, functional assays, and in vivo validation; >1000 citations","pmids":["16940167"],"is_preprint":false},{"year":2010,"finding":"CXCR7 functions as a scavenger receptor for CXCL11 and CXCL12, mediating constitutive ligand internalization and targeting chemokines for lysosomal degradation without G-protein coupling; CXCR7 continuously cycles between plasma membrane and intracellular compartments in both mammalian cells and zebrafish.","method":"Ligand internalization assays, degradation assays, live-cell imaging/receptor cycling assays in mammalian cells and zebrafish; active CXCL12 sequestration demonstrated in mouse heart valves and human umbilical vein endothelium","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods, replicated across cell types and in vivo tissues, mechanistic insight into scavenging pathway","pmids":["20161793"],"is_preprint":false},{"year":2004,"finding":"CXCL11 uses distinct intracellular domains of CXCR3 for internalization: the third intracellular loop is predominantly required for CXCL11-induced CXCR3 internalization, whereas CXCL9 and CXCL10 require the carboxyl-terminal domain and beta-arrestin1. All three ligands require the carboxyl terminus and DRY sequence for chemotaxis and calcium mobilization.","method":"CXCR3 deletion/point mutants expressed in cells, internalization assays, chemotaxis assays, calcium mobilization assays, beta-arrestin co-immunoprecipitation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — receptor mutagenesis with multiple functional readouts; identifies mechanistically distinct signaling domains for CXCL11 vs. other ligands","pmids":["15150261"],"is_preprint":false},{"year":2002,"finding":"Dipeptidyl peptidase IV (DPP IV/CD26) expressed on T cells cleaves CXCL11 at its N-terminus (removing two residues to generate CXCL11(3-73)), reducing CXCR3 binding ~8-fold, completely abolishing calcium flux and chemotaxis, but retaining partial CXCR3 downregulation activity so the truncated form desensitizes T cells to intact CXCL11.","method":"DPP IV inhibitor experiments, mass spectrometry characterization of cleavage product, calcium flux assays, chemotaxis assays, CXCR3 binding assays with T cells and transfectants","journal":"Journal of leukocyte biology","confidence":"High","confidence_rationale":"Tier 1 — enzymatic cleavage characterized biochemically, truncation product functionally validated with multiple assays","pmids":["12101279"],"is_preprint":false},{"year":2008,"finding":"Matrix metalloproteinases MMP-8, MMP-12, and MMP-9 cleave CXCL11 at both amino and carboxyl termini, generating CXCL11-(5-73), -(5-63), and -(5-58) forms. N-terminal truncation converts CXCL11 from a CXCR3 agonist to an antagonist with enhanced heparin affinity (CXCL11-(5-73)); further C-terminal truncation to position 58 abolishes both antagonist activity and heparin binding.","method":"MALDI-TOF mass spectrometry identification of cleavage products, calcium mobilization assays, chemotaxis assays with CXCR3 transfectants and human T lymphocytes, heparin binding assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — biochemical characterization of cleavage products combined with multiple functional assays and structure-activity analysis","pmids":["18411283"],"is_preprint":false},{"year":2008,"finding":"Peptidylarginine deiminase (PAD) citrullinates CXCL11 by converting arginine to citrulline, impairing CXCR3 signaling and T-cell activation without altering receptor binding, and reducing heparin binding properties of CXCL11.","method":"In vitro citrullination with rabbit PAD and human PAD2, mass spectrometry, calcium mobilization assays, chemotaxis assays, heparin binding assays, CXCR3 binding assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 — biochemical modification characterized with multiple functional readouts; identifies naturally occurring PTM","pmids":["18645041"],"is_preprint":false},{"year":2004,"finding":"CXCL11 acts as a natural antagonist for CCR5: it inhibits MIP-1α/CCL3 binding to CCR5-transfected cells and monocytes, and blocks CCR5-mediated cell migration, calcium release, and actin polymerization; structural analysis implicates residues K17, K49, and Q51 of CXCL11 in CCR5 binding.","method":"Competitive binding assays, chemotaxis assays, calcium flux assays, actin polymerization assays with CCR5 transfectants and primary monocytes; structure-activity analysis","journal":"Journal of leukocyte biology","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal functional assays with both transfected cells and primary cells; structure-activity analysis","pmids":["15178708"],"is_preprint":false},{"year":2004,"finding":"NMR solution structure of CXCL11 reveals the canonical chemokine fold with greater conformational flexibility than related chemokines; CXCL11 contains a beta-bulge in beta-strand 1 that distorts the dimerization interface and prevents dimer formation at millimolar concentrations, unlike CXCL10 and IL-8.","method":"Solution NMR structure determination","journal":"Protein science","confidence":"High","confidence_rationale":"Tier 1 — NMR structure with structural validation and comparison to related chemokines","pmids":["15273303"],"is_preprint":false},{"year":2005,"finding":"CXCL11 (IP-9) promotes keratinocyte motility via CXCR3 signaling through a pathway requiring phospholipase C-β3-dependent intracellular calcium flux and selective activation of mu-calpain (calpain 1), leading to cleavage of focal adhesion kinase and disassembly of vinculin aggregates; this is distinct from EGF-induced motility which requires M-calpain (calpain 2).","method":"In vitro wound healing assay, pharmacological inhibitors of PLC-β3 and calcium chelation, RNAi-mediated depletion of calpain 1 vs. calpain 2, focal adhesion kinase cleavage assays, vinculin immunofluorescence","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 — RNAi distinguishing calpain isoforms with multiple downstream readouts; mechanistic pathway from receptor to cytoskeletal effectors","pmids":["15713646"],"is_preprint":false},{"year":1999,"finding":"IFN-beta induction of CXCL11 (beta-R1/I-TAC) requires catalytically active TYK2 kinase; cells expressing kinase-deficient TYK2 mutants fail to induce CXCL11 despite normal expression of other IFN-stimulated genes, indicating CXCL11 induction depends on an accessory TYK2-dependent signaling pathway beyond the canonical ISGF3/ISRE pathway.","method":"TYK2-deficient U1 cell complementation with wild-type or kinase-dead TYK2 mutants, promoter-reporter transfection assays, comparison of CXCL11 vs. other ISG induction","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — genetic complementation with kinase-dead mutants and promoter assays; identifies specific signaling requirement for CXCL11 gene induction","pmids":["9890942"],"is_preprint":false},{"year":2007,"finding":"CXCL11 gene induction by IFN requires STAT3 in a non-canonical manner: STAT3 is required but Y705 phosphorylation is not needed; STAT3 recruits transcriptional activators NF-κB p65 and IRF1 to the CXCL11 promoter, while its absence leads to binding of repressors p50 and IRF2.","method":"STAT3-deficient cell lines, wild-type and Y705F STAT3 reconstitution, chromatin immunoprecipitation assays of CXCL11 promoter, promoter-reporter assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1–2 — ChIP assays with genetic reconstitution and promoter-reporter validation; identifies non-canonical STAT3 requirement","pmids":["17202361"],"is_preprint":false},{"year":2016,"finding":"PRMT5-mediated symmetric dimethylation of NF-κB p65 at Arg174 is required for TNF-α plus IFN-γ-induced CXCL11 gene expression in endothelial cells; p65 Arg174Ala or Arg174Lys mutants fail to associate with the CXCL11 promoter, and PRMT5 knockdown reduces CXCL11 mRNA and protein.","method":"PRMT5 RNAi, p65 Arg174 mutant reconstitution, mass spectrometric identification of methylation site, ChIP and Re-ChIP assays at CXCL11 promoter","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 — biochemical identification of methylation site by MS combined with genetic reconstitution and ChIP; identifies specific PTM writer and target residue for CXCL11 transcriptional regulation","pmids":["26901772"],"is_preprint":false},{"year":2010,"finding":"GAG-binding epitope of CXCL11 maps primarily to the C-terminal helix residues K57-K58-Q-A-R62 plus K17; mutation of these residues impairs heparin binding in vitro and abolishes in vivo cell migration despite retained receptor binding and near-normal in vitro chemotaxis, establishing a requirement for GAG interactions for CXCL11 in vivo function. CXCL11 also exhibits two affinity states for both heparin and CXCR3, likely related to its conformational flexibility.","method":"Alanine-scanning mutagenesis of basic residue clusters, in vitro heparin binding assays, CXCR3 binding assays, in vitro and in vivo cell migration assays, NMR HSQC spectra","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — systematic mutagenesis with multiple biochemical and functional assays including in vivo validation","pmids":["20363748"],"is_preprint":false},{"year":2005,"finding":"CXCL11 has potent in vivo antitumor activity mediated primarily through recruitment of CD8+CXCR3+ T lymphocytes rather than inhibition of angiogenesis; in vivo CD8+ T cell depletion completely abolished the antitumor effect, and surviving mice developed protective antitumor immunity.","method":"EL4 tumor cells genetically modified to produce murine CXCL11, in vivo tumor growth assays, flow cytometric analysis of tumor infiltrates, in vivo CD8 T cell depletion, rechallenge experiments, IFN-γ production assays, angiogenesis assessment","journal":"Journal of immunotherapy","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic model with depletion experiments and multiple readouts; clearly establishes CD8 T cell-dependent mechanism","pmids":["16000952"],"is_preprint":false},{"year":2014,"finding":"CXCL11/CXCR3 engagement drives an immunotolerizing state (IL-10hi Tr1 and IL-4hi Th2 cells) via p70 kinase/mTOR in STAT3- and STAT6-dependent pathways, whereas CXCL10/CXCR3 drives effector Th1 polarization via STAT1, STAT4, and STAT5. A CXCL11-Ig fusion induced remission and prevented relapse in EAE mouse model.","method":"T cell polarization assays, phospho-STAT Western blots, mTOR pathway inhibitors, CXCL11-Ig fusion protein therapeutic study in SJL/J EAE model, GFP T cell trafficking assays","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1–2 — distinct signaling pathways identified by multiple pharmacological and genetic approaches; functional validation in disease model; mechanistically distinguishes CXCL11 from CXCL10 signaling through same receptor","pmids":["24713654"],"is_preprint":false},{"year":2005,"finding":"CXCL11 attenuates bleomycin-induced pulmonary fibrosis by inhibiting angiogenesis and reducing pulmonary endothelial cell numbers; CXCR3 is not expressed on fibroblasts and CXCL11 has no direct effect on pulmonary fibroblasts, indicating the antifibrotic mechanism is indirect via vascular remodeling.","method":"In vivo bleomycin mouse model with systemic CXCL11 administration, collagen deposition assays, procollagen gene expression, histopathology, angiogenesis quantification, endothelial cell counting, CXCR3 expression analysis on fibroblasts","journal":"American journal of respiratory and critical care medicine","confidence":"High","confidence_rationale":"Tier 2 — in vivo model with mechanistic exclusion of direct fibroblast effects; multiple complementary readouts","pmids":["15502109"],"is_preprint":false},{"year":2012,"finding":"CXCL10 and CXCL11 are allosteric ligands of CXCR3 that engage distinct receptor conformations: CXCR3 mutants D112N, D195N, and E196Q respond to CXCL11 but not CXCL10 or synthetic agonists, indicating CXCL11 recognition by CXCR3 is largely independent of D112 and extracellular loop residues D195/E196 required for CXCL10.","method":"CXCR3 point mutant generation, radioligand binding, chemotaxis assays with natural and synthetic ligands, molecular modelling","journal":"British journal of pharmacology","confidence":"Medium","confidence_rationale":"Tier 1–2 — mutagenesis with functional validation but single lab; molecular modelling supports interpretation","pmids":["21895630"],"is_preprint":false},{"year":2016,"finding":"ACKR3/CXCR7 binds CXCL11 through a different binding mode than CXCL12: CXCL11 requires the ACKR3 N-terminus and extracellular loop residues for primary binding and ECL residues for arrestin recruitment, while CXCL12 requires key residues D179 and D275 with no evident N-terminal involvement. Mutations reducing CXCL11 binding also impair scavenging; scavenging does not correlate with arrestin recruitment.","method":"30 ACKR3 substitution mutants, radioligand competition binding, β-arrestin recruitment assays, chemokine scavenging assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — comprehensive mutagenesis with three independent functional readouts; defines binding mode differences for two ACKR3 ligands","pmids":["27875312"],"is_preprint":false},{"year":2005,"finding":"CXCL9, CXCL10, and CXCL11 activate PI3K, MAPK, and actin reorganization in intestinal myofibroblasts through a Gαi-independent (pertussis toxin-insensitive) mechanism; CXCL11 uniquely elevates intracellular calcium in these cells despite no detectable surface CXCR3 expression, suggesting a variant or modified receptor coupling mechanism.","method":"PI3K and MAPK activation assays, actin reorganization assays, pertussis toxin treatment, calcium flux assays, CXCR3 surface expression analysis in intestinal myofibroblasts","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple functional assays in primary cell type; novel finding of Gαi-independent signaling but receptor identity unresolved","pmids":["16210647"],"is_preprint":false},{"year":2005,"finding":"CXCL11-induced CXCR3-dependent cell migration requires the membrane proximal carboxyl terminus (including the LLL motif) for internalization and migration, and the third intracellular loop S245 for integrin-dependent adhesion, actin polymerization, and migration at high CXCL11 concentrations; pertussis toxin inhibits CXCL11-induced migration confirming Gαi dependence in HEK 293 cells.","method":"CXCR3 carboxyl-terminus and third intracellular loop mutants expressed in HEK 293 cells, migration assays, internalization assays, calcium flux, integrin adhesion assays, actin polymerization assays, pertussis toxin treatment","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 — systematic receptor mutagenesis with multiple functional assays distinguishing adhesion from migration and internalization","pmids":["16368892"],"is_preprint":false},{"year":2008,"finding":"EBV-encoded miRNA BHRF1-3 directly targets CXCL11/I-TAC mRNA; expression of BHRF1-3 inversely correlates with CXCL11 levels, and suppression of CXCL11 is reversed by transfection of antisense oligonucleotides to BHRF1-3.","method":"EBV miRNA expression profiling in primary lymphomas, inverse correlation analysis, antisense oligonucleotide rescue experiments","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2–3 — antisense rescue confirms functional targeting but full miRNA:mRNA interaction not validated by luciferase assay in this study","pmids":["18316607"],"is_preprint":false},{"year":2005,"finding":"IFN-beta preferentially inhibits osteoclastogenesis compared to IFN-alpha2 (100-fold more potent); expression profiling identified CXCL11 as the only gene differentially upregulated by IFN-beta, and recombinant CXCL11 alone inhibits osteoclastic differentiation, indicating CXCL11 mediates part of the anti-osteoclastogenic effect of IFN-beta via autocrine signaling.","method":"Monocyte osteoclastic differentiation assays, IFN-alpha vs. IFN-beta treatment comparison, genome-wide expression profiling, recombinant CXCL11 treatment of differentiating monocytes","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 2 — expression profiling to identify candidate, confirmed with recombinant protein functional assay; clear mechanistic link between IFN-beta signaling and CXCL11-dependent osteoclastogenesis inhibition","pmids":["16081539"],"is_preprint":false},{"year":2006,"finding":"CXCL11 promotes endometrial stromal cell proliferation via CXCR3 through p42/44 MAPK pathway activation, while inducing apoptosis of endometrial epithelial cells; IFN-gamma stimulates endometrial epithelial cells to produce CXCL11 which attracts trophoblast cells and T cells via CXCR3.","method":"Primary endometrial cell cultures, BrdU incorporation assays, lactate dehydrogenase release, annexin V staining, PD98059 MAPK inhibitor, immunoneutralization with anti-CXCL11 antibody, chemotaxis assays","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple functional assays with inhibitor and neutralization; cell-type-specific opposing effects established","pmids":["17142784"],"is_preprint":false},{"year":2008,"finding":"CXCL11 is secreted in a polarized basolateral-to-apical gradient by bronchial epithelial cells in COPD, driving T cell egression (transepithelial migration from interstitium to airway lumen) dependent on α4 and LFA-1 integrins, without requiring epithelial barrier disruption.","method":"Transepithelial resistance measurements, T cell migration assays across intact bronchial epithelium, integrin-blocking antibodies, CXCL11 localization by immunofluorescence, COPD patient biopsies","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — functional migration assays with specific integrin blockade and directional gradient established; polarized CXCL11 shown in patient tissue","pmids":["18209084"],"is_preprint":false},{"year":2008,"finding":"CXCL11 (IP-9/I-TAC) produced by re-differentiating keratinocytes is required for wound repair: mice with antisense-mediated elimination of IP-9 expression during wound healing exhibit delayed re-epithelialization, hypercellular immature dermis, persistent provisional matrix components, and severely diminished basement membrane components (laminin V and collagen IV) without altered inflammatory response.","method":"Antisense transgenic mouse model (IP-9AS), full and partial thickness excisional wounds, histological analysis over 2 months, immunohistochemistry for matrix components","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 2 — in vivo loss-of-function genetic model with multiple tissue-level readouts; establishes specific role of CXCL11 in wound maturation","pmids":["18669615"],"is_preprint":false},{"year":2019,"finding":"Docetaxel induces ROS-dependent HMGB1 release from tumor cells; HMGB1 then stimulates CXCL11 secretion via NF-κB activation, and CXCL11 enhances CD8+ T cell recruitment to the tumor microenvironment through CXCR3.","method":"Flow cytometry, immunofluorescence, Western blotting for HMGB1 and CXCL11, recombinant HMGB1 stimulation of CXCL11 production, ROS inhibition, NF-κB pathway analysis, in vivo CAR T cell recruitment assays","journal":"Journal for immunotherapy of cancer","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic pathway established with multiple orthogonal methods in vitro and in vivo; identifies HMGB1-NF-κB-CXCL11 axis","pmids":["30744691"],"is_preprint":false},{"year":2017,"finding":"STAT2 regulates CXCL11 expression specifically in response to IFNα in keratinocytes; siRNA knockdown of STAT2 reduces IFNα-induced CXCL11 and CCL5 expression among 102 cytokines tested. This STAT2-dependent regulation of CXCL11 also requires IRF9 but not STAT1 or STAT6.","method":"STAT2 siRNA knockdown in human keratinocytes, 102-cytokine multiplex analysis, IFNα stimulation, IRF9/STAT1/STAT6 knockdown experiments","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — gene-specific knockdown with broad cytokine screen identifying CXCL11 as selectively regulated; IRF9 dependence confirmed","pmids":["28472186"],"is_preprint":false},{"year":2021,"finding":"RBM15 enhances CXCL11 mRNA stability in an m6A-dependent manner in ccRCC cells; elevated RBM15 (driven by EP300/CBP-mediated histone acetylation of its promoter) increases CXCL11 secretion, which promotes macrophage infiltration and M2 polarization.","method":"RBM15 knockdown/overexpression, CXCL11 mRNA stability assays, m6A modification assays, ChIP for H3 acetylation, macrophage co-culture, in vivo xenograft models","journal":"Free radical biology & medicine","confidence":"Medium","confidence_rationale":"Tier 2 — m6A-dependent mRNA stability mechanism supported by multiple molecular and functional assays","pmids":["35381326"],"is_preprint":false},{"year":2018,"finding":"Estrogen receptor α (ERα) directly binds the CXCR7 promoter in ovarian cancer cells to upregulate CXCR7 expression in response to estrogen; CXCL11 is also upregulated by estrogen, and CXCL11-induced ERα Ser-118 phosphorylation creates a positive feedback loop reinforcing CXCR7 transcription. CXCR7 (not CXCR3) mediates estrogen-induced mesenchymal marker expression and cancer cell migration.","method":"ChIP for ERα at CXCR7 promoter, histone modification analysis, CXCR7 siRNA knockdown, CXCL11-dependent ERα phosphorylation assays, cell migration assays, laser-capture microdissection of clinical samples","journal":"Molecular oncology","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP, phosphorylation assays, and functional rescue establish feedback mechanism; validated in clinical specimens","pmids":["30051594"],"is_preprint":false},{"year":2015,"finding":"The CXCR3-CXCL11 signaling axis mediates macrophage chemotaxis to bacterial infection sites in zebrafish; loss of the zebrafish CXCR3 ortholog (cxcr3.2) attenuates macrophage recruitment to infection foci, reduces granuloma formation, limits mycobacterial dissemination, and decreases bacterial burden. Recombinant CXCL11-like chemokines exert Cxcr3.2-dependent chemoattraction in vivo.","method":"Zebrafish cxcr3.2 mutant analysis, NBI74330 CXCR3 antagonist treatment, in vivo injection of recombinant CXCL11-like proteins, M. marinum infection model, macrophage migration imaging, granuloma quantification","journal":"Disease models & mechanisms","confidence":"High","confidence_rationale":"Tier 2 — genetic and pharmacological loss-of-function with receptor-specific rescue; conserved function validated across vertebrates","pmids":["25573892"],"is_preprint":false},{"year":2007,"finding":"IL-18 enhances IFN-γ-induced CXCL9, CXCL10, and CXCL11 production in human keratinocytes by activating NF-κB, STAT1, and IRF-1 through PI3K/Akt and MEK/ERK pathways; antisense oligonucleotides against NF-κB p50, p65, or STAT1 suppress CXCL11 production, and antisense IRF-1 specifically suppresses CXCL11.","method":"Cytokine stimulation of primary keratinocytes, ELISA, antisense oligonucleotides against transcription factors, PI3K/p38 MAPK/MEK inhibitors, phosphorylation assays","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — antisense knockdown and inhibitor studies identify transcription factors required for CXCL11; IRF-1 specifically required for CXCL11 vs. CXCL9/10","pmids":["17274000"],"is_preprint":false},{"year":2019,"finding":"CXCL11 promotes self-renewal, tumorigenic, and chemoresistance properties of α2δ1+ hepatocellular carcinoma tumor-initiating cells via ERK1/2 activation through CXCR3 in an autocrine manner, inducing stem cell-related genes BMI1, NANOG, MDR1, ABCG2, and CACNA2D1.","method":"CXCL11 stimulation of α2δ1+ HCC TICs, sphere formation assays, tumor initiation assays, ERK1/2 phosphorylation assays, CXCR3 receptor blocking, gene expression profiling of stemness markers","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 — CXCR3 blocking and ERK1/2 pathway inhibition establish receptor-pathway linkage with functional readouts","pmids":["30771435"],"is_preprint":false}],"current_model":"CXCL11 is an IFN-γ-inducible non-ELR CXC chemokine that primarily signals through CXCR3 (with higher affinity than CXCL9/CXCL10), activating Gαi-dependent calcium flux, ERK1/2, PI3K, and mTOR/STAT3 pathways to drive T cell chemotaxis, keratinocyte migration via mu-calpain, and context-dependent immunotolerizing Tr1/Th2 polarization; it also binds CXCR7/ACKR3 as a scavenged decoy ligand and acts as a natural antagonist at CCR3 and CCR5; its activity is regulated post-translationally by DPP IV-mediated N-terminal cleavage (inactivation), MMP processing (conversion to CXCR3 antagonist), PAD-mediated citrullination (reduced signaling), glycosaminoglycan binding via C-terminal helix residues (required for in vivo gradient formation), and transcriptionally by TYK2-dependent IFN signaling, STAT2/IRF9, STAT3, NF-κB p65 Arg174 methylation by PRMT5, and miR-34a-5p/miR-206-mediated 3'UTR repression."},"narrative":{"teleology":[{"year":1998,"claim":"Establishing that CXCL11 is a CXCR3-selective chemokine with the highest receptor affinity among its family members resolved the identity and primary receptor for this IFN-inducible chemokine and defined its cellular target as activated T cells.","evidence":"Receptor binding assays, calcium flux, and chemotaxis in IL-2-activated T cells and CXCR3 transfectants","pmids":["9625760"],"confidence":"High","gaps":["Downstream intracellular signaling cascades not yet mapped","In vivo relevance of CXCR3 selectivity untested"]},{"year":1999,"claim":"Demonstrating that CXCL11 induction requires catalytically active TYK2 beyond the canonical ISGF3 pathway established that CXCL11 transcription depends on a specialized IFN signaling branch distinct from typical ISGs.","evidence":"TYK2-deficient cell complementation with kinase-dead mutants and promoter-reporter assays","pmids":["9890942"],"confidence":"High","gaps":["Downstream TYK2 substrates specific to CXCL11 induction not identified","Whether TYK2 requirement extends to IFN-γ vs. IFN-β not resolved"]},{"year":2000,"claim":"Revealing that CXCL11 acts as a natural antagonist of CCR3 expanded its functional repertoire beyond CXCR3 agonism to include counter-regulation of eosinophil chemotaxis, providing a mechanism for cross-talk between Th1 and Th2 chemokine systems.","evidence":"Competitive binding, calcium flux, and chemotaxis assays with CCR3 transfectants and human eosinophils","pmids":["11110785"],"confidence":"High","gaps":["Structural basis of CCR3 antagonism vs. CXCR3 agonism unknown","In vivo relevance of CCR3 antagonism not tested"]},{"year":2002,"claim":"Identifying DPP IV-mediated N-terminal cleavage as an inactivation mechanism established the first post-translational regulatory switch for CXCL11 and showed the truncated product acts as a desensitizing agent.","evidence":"Mass spectrometry of cleavage product, calcium flux and chemotaxis assays with T cells","pmids":["12101279"],"confidence":"High","gaps":["Relative contribution of DPP IV cleavage vs. other proteases in vivo unclear","Whether truncated CXCL11(3-73) has physiological antagonist function in tissues untested"]},{"year":2003,"claim":"Showing that CXCL11 activates CXCR3-B to mediate angiostatic effects on endothelial cells revealed that receptor splice variant usage determines whether CXCL11 promotes migration or inhibits proliferation/induces apoptosis.","evidence":"HMEC-1 transfection with CXCR3-A or CXCR3-B, radioligand binding, DNA synthesis, apoptosis assays","pmids":["12782716"],"confidence":"High","gaps":["Relative expression levels of CXCR3-A vs. CXCR3-B across tissues not systematically mapped","Signaling pathways downstream of CXCR3-B not fully delineated"]},{"year":2004,"claim":"Mapping the intracellular domains of CXCR3 required for CXCL11 vs. CXCL10/CXCL9 responses demonstrated biased agonism at the receptor level — CXCL11 uniquely requires the third intracellular loop for internalization while other ligands require the C-terminus and β-arrestin1, and CXCL11 also antagonizes CCR5 via specific surface residues.","evidence":"CXCR3 deletion/point mutants with internalization, chemotaxis, and calcium assays; CCR5 competitive binding and structure-activity analysis","pmids":["15150261","15178708"],"confidence":"High","gaps":["Whether biased signaling translates to distinct gene expression programs in T cells unknown","Crystal structure of CXCL11-CXCR3 complex unavailable"]},{"year":2004,"claim":"Solving the NMR structure of CXCL11 revealed a monomeric chemokine with a beta-bulge preventing dimerization, providing a structural explanation for its distinct receptor binding properties.","evidence":"Solution NMR structure determination","pmids":["15273303"],"confidence":"High","gaps":["No CXCL11-receptor complex structure","Functional significance of obligate monomerism vs. other CXCR3 ligands unexplored"]},{"year":2005,"claim":"Multiple 2005 studies established diverse biological outputs: CXCL11 promotes keratinocyte wound healing via PLC-β3/μ-calpain/FAK cleavage, drives CD8+ T cell-dependent antitumor immunity in vivo, inhibits osteoclastogenesis downstream of IFN-β, and is required for wound maturation in vivo.","evidence":"RNAi distinguishing calpain isoforms in keratinocytes; EL4 tumor model with CD8 depletion; monocyte osteoclast differentiation assays; antisense transgenic wound model","pmids":["15713646","16000952","16081539","18669615"],"confidence":"High","gaps":["Whether μ-calpain pathway operates in non-keratinocyte CXCR3+ cells unknown","Relative contribution of CXCL11 vs. CXCL9/10 to CD8 T cell tumor recruitment not dissected"]},{"year":2006,"claim":"Identifying CXCR7 as a high-affinity alternate receptor for CXCL11 that does not couple to G-proteins but promotes cell survival and adhesion revealed a second receptor system operating as a ligand sink.","evidence":"Radioligand binding, calcium and migration assays (negative), adhesion and tumor growth assays in vivo","pmids":["16940167"],"confidence":"High","gaps":["Signaling pathways downstream of CXCR7 upon CXCL11 binding not identified","Relative contribution of CXCR7 scavenging to CXCL11 gradient shaping in vivo unclear"]},{"year":2007,"claim":"Demonstrating that STAT3 (independent of Y705 phosphorylation) scaffolds NF-κB p65 and IRF1 onto the CXCL11 promoter while its absence permits repressor binding resolved the non-canonical transcription factor requirement for CXCL11 induction.","evidence":"STAT3-deficient cells with WT/Y705F reconstitution, ChIP at CXCL11 promoter, promoter-reporter assays","pmids":["17202361"],"confidence":"High","gaps":["Direct protein-protein interaction between unphosphorylated STAT3, p65, and IRF1 not biochemically reconstituted","Whether this non-canonical STAT3 mechanism operates in all CXCL11-producing cell types untested"]},{"year":2008,"claim":"Characterizing MMP-mediated proteolytic processing and PAD-mediated citrullination as two additional post-translational regulatory mechanisms showed that CXCL11 can be converted from agonist to antagonist (by MMPs) or functionally attenuated (by citrullination), with C-terminal truncation ablating both receptor and GAG binding.","evidence":"MALDI-TOF MS of MMP cleavage products with chemotaxis/heparin binding; PAD citrullination with MS and functional assays","pmids":["18411283","18645041"],"confidence":"High","gaps":["In vivo prevalence of citrullinated vs. MMP-truncated CXCL11 forms unknown","Which MMP family members are most relevant in specific tissue contexts not established"]},{"year":2010,"claim":"Mapping the GAG-binding epitope to C-terminal helix residues K57-K58-R62 and K17 and showing that GAG-binding mutants fail in vivo despite normal in vitro chemotaxis established that heparan sulfate immobilization is essential for CXCL11 gradient function in tissues; separately, CXCR7 was confirmed as a constitutively cycling scavenger that internalizes and degrades CXCL11.","evidence":"Alanine-scanning mutagenesis with in vitro/in vivo migration assays; live-cell imaging of CXCR7 cycling and ligand degradation in mammalian cells and zebrafish","pmids":["20363748","20161793"],"confidence":"High","gaps":["Tissue-specific GAG composition effects on CXCL11 gradient formation unknown","Relative quantitative contribution of CXCR7 vs. DPP IV/MMPs to CXCL11 clearance in vivo not determined"]},{"year":2014,"claim":"Demonstrating that CXCL11 and CXCL10 activate distinct signaling cascades through the same receptor — CXCL11 driving mTOR/STAT3/STAT6-dependent Tr1/Th2 tolerance vs. CXCL10 driving STAT1/4/5-dependent Th1 immunity — resolved a long-standing puzzle of how three ligands sharing one receptor produce opposing immunological outcomes.","evidence":"T cell polarization, phospho-STAT blots, mTOR inhibitors, CXCL11-Ig fusion therapeutic in EAE model","pmids":["24713654"],"confidence":"High","gaps":["Structural basis for biased agonism at CXCR3 not determined","Whether tolerance-inducing pathway operates in all T cell subsets or disease contexts unknown"]},{"year":2016,"claim":"Identifying PRMT5-mediated Arg174 dimethylation of NF-κB p65 as required for p65 association with the CXCL11 promoter added an epigenetic regulatory layer to CXCL11 transcription; separately, systematic ACKR3 mutagenesis revealed a CXCL11 binding mode distinct from CXCL12, with scavenging decoupled from arrestin recruitment.","evidence":"PRMT5 RNAi, p65 R174 mutant reconstitution, ChIP/Re-ChIP; 30 ACKR3 substitution mutants with binding, arrestin, and scavenging assays","pmids":["26901772","27875312"],"confidence":"High","gaps":["Whether PRMT5-p65 methylation is a general NF-κB target gene mechanism or CXCL11-selective unclear","ACKR3-mediated signaling events independent of G-proteins and arrestins not identified"]},{"year":2017,"claim":"Establishing STAT2/IRF9 (but not STAT1) as required for IFNα-induced CXCL11 expression in keratinocytes identified a cell-type-specific transcriptional input distinct from the STAT3/IRF1 axis described in other contexts.","evidence":"STAT2 siRNA in keratinocytes, 102-cytokine multiplex screen, IRF9/STAT1/STAT6 knockdowns","pmids":["28472186"],"confidence":"Medium","gaps":["Whether STAT2/IRF9 and STAT3/IRF1 pathways converge or operate in distinct cell types not resolved","Promoter occupancy by STAT2/IRF9 not demonstrated by ChIP in this study"]},{"year":2019,"claim":"Two studies extended CXCL11 biology to tumor microenvironment signaling: docetaxel-induced HMGB1 stimulates CXCL11 via NF-κB to recruit CD8+ T cells, while autocrine CXCL11/CXCR3/ERK1/2 signaling maintains stemness in hepatocellular carcinoma tumor-initiating cells.","evidence":"HMGB1-NF-κB-CXCL11 pathway analysis with ROS inhibition and in vivo CAR T recruitment; CXCR3 blocking and ERK inhibition in HCC sphere assays","pmids":["30744691","30771435"],"confidence":"Medium","gaps":["Whether CXCL11-driven stemness operates in tumor types beyond HCC untested","Relative importance of CXCL11 vs. CXCL9/10 in docetaxel-induced immune recruitment not quantified"]},{"year":2021,"claim":"Showing that RBM15 stabilizes CXCL11 mRNA via m6A modification to promote macrophage infiltration and M2 polarization in ccRCC introduced epitranscriptomic regulation as a mechanism controlling CXCL11 abundance.","evidence":"RBM15 knockdown/overexpression, m6A assays, mRNA stability measurements, macrophage co-culture, xenograft models","pmids":["35381326"],"confidence":"Medium","gaps":["Specific m6A sites on CXCL11 mRNA not mapped","Whether m6A-dependent regulation operates outside ccRCC unclear","Reader proteins mediating m6A-dependent CXCL11 stability not identified"]},{"year":null,"claim":"Key unresolved questions include the structural basis of biased agonism at CXCR3 (no CXCL11-CXCR3 complex structure exists), the in vivo quantitative hierarchy among the multiple post-translational regulatory mechanisms (DPP IV, MMPs, PAD, CXCR7 scavenging), and whether CXCL11's immunotolerizing signaling can be therapeutically harnessed independently of its chemotactic function.","evidence":"","pmids":[],"confidence":"Low","gaps":["No atomic-resolution CXCL11-CXCR3 complex structure","Quantitative in vivo contribution of each proteolytic/PTM pathway to CXCL11 regulation not established","Therapeutic separation of tolerogenic vs. chemotactic functions not achieved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,1,2,9,11,16,17]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[2,9]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,26,27,28]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,16,17,28,32]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[5,11,17,22,34]}],"complexes":[],"partners":["CXCR3","ACKR3","CCR3","CCR5","DPP4"],"other_free_text":[]},"mechanistic_narrative":"CXCL11 is an interferon-inducible, non-ELR CXC chemokine that functions as the highest-affinity ligand for CXCR3, driving chemotaxis of activated T cells, macrophages, and keratinocytes while also acting as a natural antagonist at CCR3 and CCR5 and serving as a scavenged ligand for the decoy receptor CACKR3/CXCR7 [PMID:9625760, PMID:11110785, PMID:15178708, PMID:16940167]. Signaling through CXCR3 activates Gαi-dependent calcium flux, PLC-β3/μ-calpain-mediated focal adhesion disassembly in keratinocytes, ERK1/2-driven proliferation and stemness programs, and an mTOR/STAT3/STAT6-dependent immunotolerizing pathway that polarizes T cells toward Tr1/Th2 fates — distinguishing CXCL11 from the Th1-promoting ligand CXCL10 despite sharing the same receptor [PMID:15713646, PMID:24713654, PMID:30771435]. CXCL11 activity is tightly regulated post-translationally: DPP IV N-terminal cleavage abolishes agonism, MMP-mediated truncation converts it to a CXCR3 antagonist, citrullination by PAD impairs signaling, and C-terminal helix residues mediating glycosaminoglycan binding are required for in vivo gradient formation and leukocyte recruitment [PMID:12101279, PMID:18411283, PMID:18645041, PMID:20363748]. Transcriptional induction requires TYK2 kinase activity, a non-canonical unphosphorylated STAT3 scaffold that recruits NF-κB p65 and IRF1 to the promoter, STAT2/IRF9 in response to IFNα, and PRMT5-dependent symmetric dimethylation of p65 Arg174 [PMID:9890942, PMID:17202361, PMID:28472186, PMID:26901772]."},"prefetch_data":{"uniprot":{"accession":"O14625","full_name":"C-X-C motif chemokine 11","aliases":["Beta-R1","H174","Interferon gamma-inducible protein 9","IP-9","Interferon-inducible T-cell alpha chemoattractant","I-TAC","Small-inducible cytokine B11"],"length_aa":94,"mass_kda":10.4,"function":"Chemotactic for interleukin-activated T-cells but not unstimulated T-cells, neutrophils or monocytes. Induces calcium release in activated T-cells. Binds to CXCR3. May play an important role in CNS diseases which involve T-cell recruitment. May play a role in skin immune responses","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/O14625/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CXCL11","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CXCL11","total_profiled":1310},"omim":[{"mim_id":"619589","title":"BRAF-ACTIVATED NONCODING RNA; BANCR","url":"https://www.omim.org/entry/619589"},{"mim_id":"610376","title":"ATYPICAL CHEMOKINE RECEPTOR 3; ACKR3","url":"https://www.omim.org/entry/610376"},{"mim_id":"605980","title":"NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN PROTEIN 1; NOD1","url":"https://www.omim.org/entry/605980"},{"mim_id":"605398","title":"CHEMOKINE, CXC MOTIF, LIGAND 16; CXCL16","url":"https://www.omim.org/entry/605398"},{"mim_id":"604852","title":"CHEMOKINE, CXC MOTIF, LIGAND 11; CXCL11","url":"https://www.omim.org/entry/604852"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":11.1}],"url":"https://www.proteinatlas.org/search/CXCL11"},"hgnc":{"alias_symbol":["H174","b-R1","I-TAC","IP-9"],"prev_symbol":["SCYB9B","SCYB11"]},"alphafold":{"accession":"O14625","domains":[{"cath_id":"2.40.50.40","chopping":"28-90","consensus_level":"high","plddt":82.8865,"start":28,"end":90}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O14625","model_url":"https://alphafold.ebi.ac.uk/files/AF-O14625-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O14625-F1-predicted_aligned_error_v6.png","plddt_mean":79.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CXCL11","jax_strain_url":"https://www.jax.org/strain/search?query=CXCL11"},"sequence":{"accession":"O14625","fasta_url":"https://rest.uniprot.org/uniprotkb/O14625.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O14625/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O14625"}},"corpus_meta":[{"pmid":"29207310","id":"PMC_29207310","title":"CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy.","date":"2017","source":"Cancer treatment reviews","url":"https://pubmed.ncbi.nlm.nih.gov/29207310","citation_count":1157,"is_preprint":false},{"pmid":"16940167","id":"PMC_16940167","title":"A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development.","date":"2006","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16940167","citation_count":1069,"is_preprint":false},{"pmid":"9625760","id":"PMC_9625760","title":"Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3.","date":"1998","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9625760","citation_count":690,"is_preprint":false},{"pmid":"12782716","id":"PMC_12782716","title":"An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.","date":"2003","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12782716","citation_count":587,"is_preprint":false},{"pmid":"20161793","id":"PMC_20161793","title":"CXCR7 functions as a scavenger for CXCL12 and CXCL11.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20161793","citation_count":388,"is_preprint":false},{"pmid":"10092813","id":"PMC_10092813","title":"The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10092813","citation_count":301,"is_preprint":false},{"pmid":"11523046","id":"PMC_11523046","title":"Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation.","date":"2001","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11523046","citation_count":289,"is_preprint":false},{"pmid":"10843708","id":"PMC_10843708","title":"Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10843708","citation_count":261,"is_preprint":false},{"pmid":"18316607","id":"PMC_18316607","title":"EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18316607","citation_count":259,"is_preprint":false},{"pmid":"11110785","id":"PMC_11110785","title":"The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11110785","citation_count":248,"is_preprint":false},{"pmid":"20487305","id":"PMC_20487305","title":"Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity--a tale of conflict and conundrum.","date":"2010","source":"Neuropathology and applied neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/20487305","citation_count":237,"is_preprint":false},{"pmid":"15150261","id":"PMC_15150261","title":"Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15150261","citation_count":215,"is_preprint":false},{"pmid":"30744691","id":"PMC_30744691","title":"Cancer-cell-secreted CXCL11 promoted CD8+ T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC.","date":"2019","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30744691","citation_count":176,"is_preprint":false},{"pmid":"36056553","id":"PMC_36056553","title":"CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma.","date":"2022","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/36056553","citation_count":167,"is_preprint":false},{"pmid":"22989616","id":"PMC_22989616","title":"Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12.","date":"2012","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/22989616","citation_count":164,"is_preprint":false},{"pmid":"29893515","id":"PMC_29893515","title":"CXCL9, CXCL10, CXCL11, and their receptor (CXCR3) in neuroinflammation and neurodegeneration.","date":"2018","source":"Advances in clinical and experimental medicine : official organ Wroclaw Medical University","url":"https://pubmed.ncbi.nlm.nih.gov/29893515","citation_count":161,"is_preprint":false},{"pmid":"17274000","id":"PMC_17274000","title":"IL-18 enhances IFN-gamma-induced production of CXCL9, CXCL10, and CXCL11 in human keratinocytes.","date":"2007","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17274000","citation_count":140,"is_preprint":false},{"pmid":"24713654","id":"PMC_24713654","title":"CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis.","date":"2014","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/24713654","citation_count":140,"is_preprint":false},{"pmid":"29399394","id":"PMC_29399394","title":"Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines.","date":"2018","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/29399394","citation_count":135,"is_preprint":false},{"pmid":"15502109","id":"PMC_15502109","title":"CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling.","date":"2004","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15502109","citation_count":131,"is_preprint":false},{"pmid":"10233762","id":"PMC_10233762","title":"Human IP-9: A keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3).","date":"1999","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/10233762","citation_count":120,"is_preprint":false},{"pmid":"32659248","id":"PMC_32659248","title":"Endothelial cells under therapy-induced senescence secrete CXCL11, which increases aggressiveness of breast cancer cells.","date":"2020","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/32659248","citation_count":119,"is_preprint":false},{"pmid":"16000952","id":"PMC_16000952","title":"The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis.","date":"2005","source":"Journal of immunotherapy (Hagerstown, Md. : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/16000952","citation_count":118,"is_preprint":false},{"pmid":"18645041","id":"PMC_18645041","title":"Citrullination of CXCL10 and CXCL11 by peptidylarginine deiminase: a naturally occurring posttranslational modification of chemokines and new dimension of immunoregulation.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18645041","citation_count":114,"is_preprint":false},{"pmid":"25573892","id":"PMC_25573892","title":"The CXCR3-CXCL11 signaling axis mediates macrophage recruitment and dissemination of mycobacterial infection.","date":"2015","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/25573892","citation_count":109,"is_preprint":false},{"pmid":"33707417","id":"PMC_33707417","title":"Cancer-associated fibroblast-derived CXCL11 modulates hepatocellular carcinoma cell migration and tumor metastasis through the circUBAP2/miR-4756/IFIT1/3 axis.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33707417","citation_count":106,"is_preprint":false},{"pmid":"12884299","id":"PMC_12884299","title":"CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11.","date":"2003","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12884299","citation_count":106,"is_preprint":false},{"pmid":"34205098","id":"PMC_34205098","title":"The Pro-Inflammatory Chemokines CXCL9, CXCL10 and CXCL11 Are Upregulated Following SARS-CoV-2 Infection in an AKT-Dependent Manner.","date":"2021","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/34205098","citation_count":105,"is_preprint":false},{"pmid":"16081539","id":"PMC_16081539","title":"Interferon-alpha and -beta differentially regulate osteoclastogenesis: role of differential induction of chemokine CXCL11 expression.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16081539","citation_count":98,"is_preprint":false},{"pmid":"26698852","id":"PMC_26698852","title":"Blocking interferon γ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis.","date":"2015","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/26698852","citation_count":98,"is_preprint":false},{"pmid":"27141352","id":"PMC_27141352","title":"CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy.","date":"2015","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/27141352","citation_count":96,"is_preprint":false},{"pmid":"15122750","id":"PMC_15122750","title":"Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation.","date":"2004","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/15122750","citation_count":95,"is_preprint":false},{"pmid":"10504443","id":"PMC_10504443","title":"The CXCR3 activating chemokines IP-10, Mig, and IP-9 are expressed in allergic but not in irritant patch test reactions.","date":"1999","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/10504443","citation_count":95,"is_preprint":false},{"pmid":"19276231","id":"PMC_19276231","title":"Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists.","date":"2009","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/19276231","citation_count":90,"is_preprint":false},{"pmid":"18411283","id":"PMC_18411283","title":"Matrix metalloproteinase processing of CXCL11/I-TAC results in loss of chemoattractant activity and altered glycosaminoglycan binding.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18411283","citation_count":84,"is_preprint":false},{"pmid":"14996826","id":"PMC_14996826","title":"Synergistic induction of CXCL9 and CXCL11 by Toll-like receptor ligands and interferon-gamma in fibroblasts correlates with elevated levels of CXCR3 ligands in septic arthritis synovial fluids.","date":"2004","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/14996826","citation_count":75,"is_preprint":false},{"pmid":"17255201","id":"PMC_17255201","title":"Prolactin enhances interferon-gamma-induced production of CXC ligand 9 (CXCL9), CXCL10, and CXCL11 in human keratinocytes.","date":"2007","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/17255201","citation_count":71,"is_preprint":false},{"pmid":"10843686","id":"PMC_10843686","title":"The murine chemokine CXCL11 (IFN-inducible T cell alpha chemoattractant) is an IFN-gamma- and lipopolysaccharide-inducible glucocorticoid-attenuated response gene expressed in lung and other tissues during endotoxemia.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10843686","citation_count":70,"is_preprint":false},{"pmid":"31110502","id":"PMC_31110502","title":"RNAseq Profiling of Leukocyte Populations in Zebrafish Larvae Reveals a cxcl11 Chemokine Gene as a Marker of Macrophage Polarization During Mycobacterial Infection.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31110502","citation_count":68,"is_preprint":false},{"pmid":"12101279","id":"PMC_12101279","title":"Dipeptidyl peptidase IV (CD26) on T cells cleaves the CXC chemokine CXCL11 (I-TAC) and abolishes the stimulating but not the desensitizing potential of the chemokine.","date":"2002","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/12101279","citation_count":63,"is_preprint":false},{"pmid":"20810571","id":"PMC_20810571","title":"CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves' and normal thyrocytes.","date":"2010","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/20810571","citation_count":63,"is_preprint":false},{"pmid":"12517732","id":"PMC_12517732","title":"A CXC chemokine sequence isolated from the rainbow trout Oncorhynchus mykiss resembles the closely related interferon-gamma-inducible chemokines CXCL9, CXCL10 and CXCL11.","date":"2002","source":"European cytokine network","url":"https://pubmed.ncbi.nlm.nih.gov/12517732","citation_count":62,"is_preprint":false},{"pmid":"15713646","id":"PMC_15713646","title":"Interferon-inducible protein 9 (CXCL11)-induced cell motility in keratinocytes requires calcium flux-dependent activation of mu-calpain.","date":"2005","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15713646","citation_count":62,"is_preprint":false},{"pmid":"24014111","id":"PMC_24014111","title":"Cancer cell-derived lymphotoxin mediates reciprocal tumour-stromal interactions in human ovarian cancer by inducing CXCL11 in fibroblasts.","date":"2014","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24014111","citation_count":61,"is_preprint":false},{"pmid":"23495770","id":"PMC_23495770","title":"Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma.","date":"2013","source":"BJU international","url":"https://pubmed.ncbi.nlm.nih.gov/23495770","citation_count":61,"is_preprint":false},{"pmid":"34905599","id":"PMC_34905599","title":"Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients.","date":"2022","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/34905599","citation_count":60,"is_preprint":false},{"pmid":"16210647","id":"PMC_16210647","title":"The chemokines CXCL9, CXCL10, and CXCL11 differentially stimulate G alpha i-independent signaling and actin responses in human intestinal myofibroblasts.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16210647","citation_count":60,"is_preprint":false},{"pmid":"17142784","id":"PMC_17142784","title":"The expression and possible roles of chemokine CXCL11 and its receptor CXCR3 in the human endometrium.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17142784","citation_count":55,"is_preprint":false},{"pmid":"20363748","id":"PMC_20363748","title":"Characterization of the chemokine CXCL11-heparin interaction suggests two different affinities for glycosaminoglycans.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20363748","citation_count":54,"is_preprint":false},{"pmid":"33137121","id":"PMC_33137121","title":"CXCL9, CXCL10, and CXCL11; biomarkers of pulmonary inflammation associated with autoimmunity in patients with collagen vascular diseases-associated interstitial lung disease and interstitial pneumonia with autoimmune features.","date":"2020","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/33137121","citation_count":52,"is_preprint":false},{"pmid":"35381326","id":"PMC_35381326","title":"Epigenetic activation of RBM15 promotes clear cell renal cell carcinoma growth, metastasis and macrophage infiltration by regulating the m6A modification of CXCL11.","date":"2022","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35381326","citation_count":52,"is_preprint":false},{"pmid":"24493023","id":"PMC_24493023","title":"Interaction of the chemokines I-TAC (CXCL11) and SDF-1 (CXCL12) in the regulation of tumor angiogenesis of colorectal cancer.","date":"2014","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/24493023","citation_count":51,"is_preprint":false},{"pmid":"30771435","id":"PMC_30771435","title":"CXCL11 promotes self-renewal and tumorigenicity of α2δ1+ liver tumor-initiating cells through CXCR3/ERK1/2 signaling.","date":"2019","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/30771435","citation_count":49,"is_preprint":false},{"pmid":"26090665","id":"PMC_26090665","title":"Effect of JAK Inhibitors on Release of CXCL9, CXCL10 and CXCL11 from Human Airway Epithelial Cells.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26090665","citation_count":49,"is_preprint":false},{"pmid":"29795466","id":"PMC_29795466","title":"Upregulation of angiostatic chemokines IP-10/CXCL10 and I-TAC/CXCL11 in human obesity and their implication for adipose tissue angiogenesis.","date":"2018","source":"International journal of obesity (2005)","url":"https://pubmed.ncbi.nlm.nih.gov/29795466","citation_count":49,"is_preprint":false},{"pmid":"18669615","id":"PMC_18669615","title":"ELR-negative CXC chemokine CXCL11 (IP-9/I-TAC) facilitates dermal and epidermal maturation during wound repair.","date":"2008","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/18669615","citation_count":46,"is_preprint":false},{"pmid":"15178708","id":"PMC_15178708","title":"I-TAC/CXCL11 is a natural antagonist for CCR5.","date":"2004","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/15178708","citation_count":46,"is_preprint":false},{"pmid":"29542173","id":"PMC_29542173","title":"MiR-206 inhibits proliferation and migration of prostate cancer cells by targeting CXCL11.","date":"2018","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/29542173","citation_count":44,"is_preprint":false},{"pmid":"31836011","id":"PMC_31836011","title":"The combination of CXCL9, CXCL10 and CXCL11 levels during primary HIV infection predicts HIV disease progression.","date":"2019","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31836011","citation_count":44,"is_preprint":false},{"pmid":"27875312","id":"PMC_27875312","title":"Mutational Analysis of Atypical Chemokine Receptor 3 (ACKR3/CXCR7) Interaction with Its Chemokine Ligands CXCL11 and CXCL12.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27875312","citation_count":43,"is_preprint":false},{"pmid":"17202361","id":"PMC_17202361","title":"Identification of CXCL11 as a STAT3-dependent gene induced by IFN.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17202361","citation_count":42,"is_preprint":false},{"pmid":"33229509","id":"PMC_33229509","title":"Wrinkle in the plan: miR-34a-5p impacts chemokine signaling by modulating CXCL10/CXCL11/CXCR3-axis in CD4+, CD8+ T cells, and M1 macrophages.","date":"2020","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33229509","citation_count":41,"is_preprint":false},{"pmid":"34088989","id":"PMC_34088989","title":"The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis.","date":"2021","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34088989","citation_count":41,"is_preprint":false},{"pmid":"21895630","id":"PMC_21895630","title":"Small molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3.","date":"2012","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21895630","citation_count":40,"is_preprint":false},{"pmid":"31437604","id":"PMC_31437604","title":"CXCL11 promotes tumor progression by the biased use of the chemokine receptors CXCR3 and CXCR7.","date":"2019","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/31437604","citation_count":38,"is_preprint":false},{"pmid":"28472186","id":"PMC_28472186","title":"STAT2 is involved in the pathogenesis of psoriasis by promoting CXCL11 and CCL5 production by keratinocytes.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28472186","citation_count":37,"is_preprint":false},{"pmid":"26239696","id":"PMC_26239696","title":"Loss of RUNX3 expression promotes cancer-associated bone destruction by regulating CCL5, CCL19 and CXCL11 in non-small cell lung cancer.","date":"2015","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26239696","citation_count":37,"is_preprint":false},{"pmid":"30425523","id":"PMC_30425523","title":"Down-regulation of CXCL11 inhibits colorectal cancer cell growth and epithelial-mesenchymal transition.","date":"2018","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30425523","citation_count":35,"is_preprint":false},{"pmid":"32035061","id":"PMC_32035061","title":"CXCL11-CXCR3 Axis Mediates Tumor Lymphatic Cross Talk and Inflammation-Induced Tumor, Promoting Pathways in Head and Neck Cancers.","date":"2020","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32035061","citation_count":34,"is_preprint":false},{"pmid":"16368892","id":"PMC_16368892","title":"Role of CXCR3 carboxyl terminus and third intracellular loop in receptor-mediated migration, adhesion and internalization in response to CXCL11.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16368892","citation_count":34,"is_preprint":false},{"pmid":"15308116","id":"PMC_15308116","title":"Expression of interferon-inducible T cell alpha chemoattractant (CXCL11) in the salivary glands of patients with Sjögren's syndrome.","date":"2004","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/15308116","citation_count":33,"is_preprint":false},{"pmid":"15322564","id":"PMC_15322564","title":"Expression of rat I-TAC/CXCL11/SCYA11 during central nervous system inflammation: comparison with other CXCR3 ligands.","date":"2004","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15322564","citation_count":33,"is_preprint":false},{"pmid":"20706716","id":"PMC_20706716","title":"Integrating individual functional moieties of CXCL10 and CXCL11 into a novel chimeric chemokine leads to synergistic antitumor effects: a strategy for chemokine-based multi-target-directed cancer therapy.","date":"2010","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/20706716","citation_count":32,"is_preprint":false},{"pmid":"29712506","id":"PMC_29712506","title":"Spinal CXCL9 and CXCL11 are not involved in neuropathic pain despite an upregulation in the spinal cord following spinal nerve injury.","date":"2018","source":"Molecular pain","url":"https://pubmed.ncbi.nlm.nih.gov/29712506","citation_count":31,"is_preprint":false},{"pmid":"24273568","id":"PMC_24273568","title":"MIG (CXCL9), IP-10 (CXCL10) and I-TAC (CXCL11) concentrations after nasal allergen challenge in patients with allergic rhinitis.","date":"2013","source":"Archives of medical science : AMS","url":"https://pubmed.ncbi.nlm.nih.gov/24273568","citation_count":31,"is_preprint":false},{"pmid":"31128616","id":"PMC_31128616","title":"Serum CXCL11 correlates with pulmonary outcomes and disease burden in sarcoidosis.","date":"2019","source":"Respiratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31128616","citation_count":30,"is_preprint":false},{"pmid":"9890942","id":"PMC_9890942","title":"Induction of beta-R1/I-TAC by interferon-beta requires catalytically active TYK2.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9890942","citation_count":30,"is_preprint":false},{"pmid":"30051594","id":"PMC_30051594","title":"Feedback control of the CXCR7/CXCL11 chemokine axis by estrogen receptor α in ovarian cancer.","date":"2018","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30051594","citation_count":30,"is_preprint":false},{"pmid":"34286440","id":"PMC_34286440","title":"CXCL11 Signaling in the Tumor Microenvironment.","date":"2021","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/34286440","citation_count":30,"is_preprint":false},{"pmid":"15273303","id":"PMC_15273303","title":"NMR structure of CXCR3 binding chemokine CXCL11 (ITAC).","date":"2004","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/15273303","citation_count":30,"is_preprint":false},{"pmid":"26901772","id":"PMC_26901772","title":"PRMT5-Mediated Methylation of NF-κB p65 at Arg174 Is Required for Endothelial CXCL11 Gene Induction in Response to TNF-α and IFN-γ Costimulation.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26901772","citation_count":29,"is_preprint":false},{"pmid":"16186347","id":"PMC_16186347","title":"Adenovirus-directed ocular innate immunity: the role of conjunctival defensin-like chemokines (IP-10, I-TAC) and phagocytic human defensin-alpha.","date":"2005","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/16186347","citation_count":29,"is_preprint":false},{"pmid":"32181005","id":"PMC_32181005","title":"Effective Treatments for Bladder Cancer Affecting CXCL9/CXCL10/CXCL11/CXCR3 Axis: A Review.","date":"2020","source":"Oman medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/32181005","citation_count":28,"is_preprint":false},{"pmid":"27926984","id":"PMC_27926984","title":"Involvement of chemokine CXCL11 in the development of morphine tolerance in rats with cancer-induced bone pain.","date":"2017","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27926984","citation_count":26,"is_preprint":false},{"pmid":"15851567","id":"PMC_15851567","title":"Synthesis of alpha-chemokines IP-10, I-TAC, and MIG are differentially regulated in human corneal keratocytes.","date":"2005","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/15851567","citation_count":26,"is_preprint":false},{"pmid":"34655278","id":"PMC_34655278","title":"Colon cancer cells secreted CXCL11 via RBP-Jκ to facilitated tumour-associated macrophage-induced cancer metastasis.","date":"2021","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34655278","citation_count":25,"is_preprint":false},{"pmid":"18209084","id":"PMC_18209084","title":"Polarized localization of epithelial CXCL11 in chronic obstructive pulmonary disease and mechanisms of T cell egression.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18209084","citation_count":25,"is_preprint":false},{"pmid":"26199110","id":"PMC_26199110","title":"Interleukin-27 and IFNγ regulate the expression of CXCL9, CXCL10, and CXCL11 in hepatitis.","date":"2015","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/26199110","citation_count":25,"is_preprint":false},{"pmid":"36504808","id":"PMC_36504808","title":"CXCL8, CXCL9, CXCL10, and CXCL11 as biomarkers of liver injury caused by chronic hepatitis B.","date":"2022","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/36504808","citation_count":24,"is_preprint":false},{"pmid":"32341359","id":"PMC_32341359","title":"The YY1/miR-548t-5p/CXCL11 signaling axis regulates cell proliferation and metastasis in human pancreatic cancer.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32341359","citation_count":24,"is_preprint":false},{"pmid":"23773308","id":"PMC_23773308","title":"Common structural interactions between the receptors CXCR3, CXCR4 and CXCR7 complexed with their natural ligands, CXCL11 and CXCL12, by a modeling approach.","date":"2013","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/23773308","citation_count":24,"is_preprint":false},{"pmid":"34534571","id":"PMC_34534571","title":"Association of chemokines IP-10/CXCL10 and I-TAC/CXCL11 with insulin resistance and enhance leukocyte endothelial arrest in obesity.","date":"2021","source":"Microvascular research","url":"https://pubmed.ncbi.nlm.nih.gov/34534571","citation_count":23,"is_preprint":false},{"pmid":"36435866","id":"PMC_36435866","title":"The LINC00152/miR-205-5p/CXCL11 axis in hepatocellular carcinoma cancer-associated fibroblasts affects cancer cell phenotypes and tumor growth.","date":"2022","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/36435866","citation_count":22,"is_preprint":false},{"pmid":"16783574","id":"PMC_16783574","title":"Colon carcinoma cells induce CXCL11-dependent migration of CXCR3-expressing cytotoxic T lymphocytes in organotypic culture.","date":"2006","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/16783574","citation_count":21,"is_preprint":false},{"pmid":"15297094","id":"PMC_15297094","title":"Glutamine and CXC chemokines IL-8, Mig, IP-10 and I-TAC in human intestinal epithelial cells.","date":"2004","source":"Clinical nutrition (Edinburgh, Scotland)","url":"https://pubmed.ncbi.nlm.nih.gov/15297094","citation_count":21,"is_preprint":false},{"pmid":"29880273","id":"PMC_29880273","title":"Serum CXCL10, CXCL11, CXCL12, and CXCL14 chemokine patterns in patients with acute liver injury.","date":"2018","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/29880273","citation_count":20,"is_preprint":false},{"pmid":"35390315","id":"PMC_35390315","title":"RAMP2-AS1 inhibits CXCL11 expression to suppress malignant phenotype of breast cancer by recruiting DNMT1 and DNMT3B.","date":"2022","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/35390315","citation_count":19,"is_preprint":false},{"pmid":"31864210","id":"PMC_31864210","title":"Bu-Shen-Fang-Chuan formula attenuates T-lymphocytes recruitment in the lung of rats with COPD through suppressing CXCL9/CXCL10/CXCL11-CXCR3 axis.","date":"2019","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/31864210","citation_count":19,"is_preprint":false},{"pmid":"38070625","id":"PMC_38070625","title":"Myostatin and CXCL11 promote nervous tissue macrophages to maintain osteoarthritis pain.","date":"2023","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/38070625","citation_count":18,"is_preprint":false},{"pmid":"31232926","id":"PMC_31232926","title":"The role of CXCR3 and its ligands CXCL10 and CXCL11 in the pathogenesis of celiac disease.","date":"2019","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31232926","citation_count":18,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":60268,"output_tokens":9670,"usd":0.162927},"stage2":{"model":"claude-opus-4-6","input_tokens":13568,"output_tokens":4785,"usd":0.281197},"total_usd":0.444124,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"CXCL11 (I-TAC) was identified as a novel non-ELR CXC chemokine that binds selectively to CXCR3 with higher affinity than CXCL9 or CXCL10, induces transient intracellular calcium mobilization and chemotactic migration in IL-2-activated T cells and CXCR3-transfected cell lines, but not in neutrophils or monocytes.\",\n      \"method\": \"Receptor binding assays, calcium flux assays, chemotaxis assays in activated T cells and CXCR3 transfectants\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal functional assays (binding, calcium flux, chemotaxis) with receptor-transfected cells; foundational discovery paper with >600 citations\",\n      \"pmids\": [\"9625760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CXCL11 binds and activates CXCR3-B, an alternatively spliced variant of CXCR3, which mediates angiostatic (anti-proliferative/pro-apoptotic) effects on endothelial cells, distinct from the pro-survival signaling of CXCR3-A.\",\n      \"method\": \"HMEC-1 transfection with CXCR3-A or CXCR3-B constructs, radioligand binding, DNA synthesis assays, apoptosis assays, signal transduction analysis\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution in transfected cells with multiple functional readouts; replicated with primary endothelial cultures; >500 citations\",\n      \"pmids\": [\"12782716\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CXCL11, CXCL9, and CXCL10 (CXCR3 agonists) act as natural antagonists for CCR3, competing for eotaxin binding to CCR3-bearing cells and inhibiting CCR3-mediated migration and Ca2+ responses without inducing CCR3 internalization; CXCL11 was the most efficacious antagonist.\",\n      \"method\": \"Competitive binding assays, calcium flux assays, chemotaxis assays with CCR3 transfectants and human eosinophils; hybrid chemokine construction\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal assays including binding competition, calcium flux, chemotaxis, and structure-function with hybrid chemokine\",\n      \"pmids\": [\"11110785\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CXCL11 (I-TAC) binds with high affinity to CXCR7 (RDC1), an alternate receptor that does not couple to G-proteins or induce calcium mobilization or cell migration, but instead confers cell survival and adhesion advantages; CXCR7 expression promotes in vivo tumor growth.\",\n      \"method\": \"Radioligand binding, calcium mobilization assays, cell migration assays, adhesion assays, small molecule antagonist studies, in vivo tumor models\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods including binding, functional assays, and in vivo validation; >1000 citations\",\n      \"pmids\": [\"16940167\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CXCR7 functions as a scavenger receptor for CXCL11 and CXCL12, mediating constitutive ligand internalization and targeting chemokines for lysosomal degradation without G-protein coupling; CXCR7 continuously cycles between plasma membrane and intracellular compartments in both mammalian cells and zebrafish.\",\n      \"method\": \"Ligand internalization assays, degradation assays, live-cell imaging/receptor cycling assays in mammalian cells and zebrafish; active CXCL12 sequestration demonstrated in mouse heart valves and human umbilical vein endothelium\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, replicated across cell types and in vivo tissues, mechanistic insight into scavenging pathway\",\n      \"pmids\": [\"20161793\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CXCL11 uses distinct intracellular domains of CXCR3 for internalization: the third intracellular loop is predominantly required for CXCL11-induced CXCR3 internalization, whereas CXCL9 and CXCL10 require the carboxyl-terminal domain and beta-arrestin1. All three ligands require the carboxyl terminus and DRY sequence for chemotaxis and calcium mobilization.\",\n      \"method\": \"CXCR3 deletion/point mutants expressed in cells, internalization assays, chemotaxis assays, calcium mobilization assays, beta-arrestin co-immunoprecipitation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — receptor mutagenesis with multiple functional readouts; identifies mechanistically distinct signaling domains for CXCL11 vs. other ligands\",\n      \"pmids\": [\"15150261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Dipeptidyl peptidase IV (DPP IV/CD26) expressed on T cells cleaves CXCL11 at its N-terminus (removing two residues to generate CXCL11(3-73)), reducing CXCR3 binding ~8-fold, completely abolishing calcium flux and chemotaxis, but retaining partial CXCR3 downregulation activity so the truncated form desensitizes T cells to intact CXCL11.\",\n      \"method\": \"DPP IV inhibitor experiments, mass spectrometry characterization of cleavage product, calcium flux assays, chemotaxis assays, CXCR3 binding assays with T cells and transfectants\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — enzymatic cleavage characterized biochemically, truncation product functionally validated with multiple assays\",\n      \"pmids\": [\"12101279\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Matrix metalloproteinases MMP-8, MMP-12, and MMP-9 cleave CXCL11 at both amino and carboxyl termini, generating CXCL11-(5-73), -(5-63), and -(5-58) forms. N-terminal truncation converts CXCL11 from a CXCR3 agonist to an antagonist with enhanced heparin affinity (CXCL11-(5-73)); further C-terminal truncation to position 58 abolishes both antagonist activity and heparin binding.\",\n      \"method\": \"MALDI-TOF mass spectrometry identification of cleavage products, calcium mobilization assays, chemotaxis assays with CXCR3 transfectants and human T lymphocytes, heparin binding assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical characterization of cleavage products combined with multiple functional assays and structure-activity analysis\",\n      \"pmids\": [\"18411283\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Peptidylarginine deiminase (PAD) citrullinates CXCL11 by converting arginine to citrulline, impairing CXCR3 signaling and T-cell activation without altering receptor binding, and reducing heparin binding properties of CXCL11.\",\n      \"method\": \"In vitro citrullination with rabbit PAD and human PAD2, mass spectrometry, calcium mobilization assays, chemotaxis assays, heparin binding assays, CXCR3 binding assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical modification characterized with multiple functional readouts; identifies naturally occurring PTM\",\n      \"pmids\": [\"18645041\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CXCL11 acts as a natural antagonist for CCR5: it inhibits MIP-1α/CCL3 binding to CCR5-transfected cells and monocytes, and blocks CCR5-mediated cell migration, calcium release, and actin polymerization; structural analysis implicates residues K17, K49, and Q51 of CXCL11 in CCR5 binding.\",\n      \"method\": \"Competitive binding assays, chemotaxis assays, calcium flux assays, actin polymerization assays with CCR5 transfectants and primary monocytes; structure-activity analysis\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal functional assays with both transfected cells and primary cells; structure-activity analysis\",\n      \"pmids\": [\"15178708\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"NMR solution structure of CXCL11 reveals the canonical chemokine fold with greater conformational flexibility than related chemokines; CXCL11 contains a beta-bulge in beta-strand 1 that distorts the dimerization interface and prevents dimer formation at millimolar concentrations, unlike CXCL10 and IL-8.\",\n      \"method\": \"Solution NMR structure determination\",\n      \"journal\": \"Protein science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structure with structural validation and comparison to related chemokines\",\n      \"pmids\": [\"15273303\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CXCL11 (IP-9) promotes keratinocyte motility via CXCR3 signaling through a pathway requiring phospholipase C-β3-dependent intracellular calcium flux and selective activation of mu-calpain (calpain 1), leading to cleavage of focal adhesion kinase and disassembly of vinculin aggregates; this is distinct from EGF-induced motility which requires M-calpain (calpain 2).\",\n      \"method\": \"In vitro wound healing assay, pharmacological inhibitors of PLC-β3 and calcium chelation, RNAi-mediated depletion of calpain 1 vs. calpain 2, focal adhesion kinase cleavage assays, vinculin immunofluorescence\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — RNAi distinguishing calpain isoforms with multiple downstream readouts; mechanistic pathway from receptor to cytoskeletal effectors\",\n      \"pmids\": [\"15713646\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"IFN-beta induction of CXCL11 (beta-R1/I-TAC) requires catalytically active TYK2 kinase; cells expressing kinase-deficient TYK2 mutants fail to induce CXCL11 despite normal expression of other IFN-stimulated genes, indicating CXCL11 induction depends on an accessory TYK2-dependent signaling pathway beyond the canonical ISGF3/ISRE pathway.\",\n      \"method\": \"TYK2-deficient U1 cell complementation with wild-type or kinase-dead TYK2 mutants, promoter-reporter transfection assays, comparison of CXCL11 vs. other ISG induction\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — genetic complementation with kinase-dead mutants and promoter assays; identifies specific signaling requirement for CXCL11 gene induction\",\n      \"pmids\": [\"9890942\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CXCL11 gene induction by IFN requires STAT3 in a non-canonical manner: STAT3 is required but Y705 phosphorylation is not needed; STAT3 recruits transcriptional activators NF-κB p65 and IRF1 to the CXCL11 promoter, while its absence leads to binding of repressors p50 and IRF2.\",\n      \"method\": \"STAT3-deficient cell lines, wild-type and Y705F STAT3 reconstitution, chromatin immunoprecipitation assays of CXCL11 promoter, promoter-reporter assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — ChIP assays with genetic reconstitution and promoter-reporter validation; identifies non-canonical STAT3 requirement\",\n      \"pmids\": [\"17202361\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PRMT5-mediated symmetric dimethylation of NF-κB p65 at Arg174 is required for TNF-α plus IFN-γ-induced CXCL11 gene expression in endothelial cells; p65 Arg174Ala or Arg174Lys mutants fail to associate with the CXCL11 promoter, and PRMT5 knockdown reduces CXCL11 mRNA and protein.\",\n      \"method\": \"PRMT5 RNAi, p65 Arg174 mutant reconstitution, mass spectrometric identification of methylation site, ChIP and Re-ChIP assays at CXCL11 promoter\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical identification of methylation site by MS combined with genetic reconstitution and ChIP; identifies specific PTM writer and target residue for CXCL11 transcriptional regulation\",\n      \"pmids\": [\"26901772\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"GAG-binding epitope of CXCL11 maps primarily to the C-terminal helix residues K57-K58-Q-A-R62 plus K17; mutation of these residues impairs heparin binding in vitro and abolishes in vivo cell migration despite retained receptor binding and near-normal in vitro chemotaxis, establishing a requirement for GAG interactions for CXCL11 in vivo function. CXCL11 also exhibits two affinity states for both heparin and CXCR3, likely related to its conformational flexibility.\",\n      \"method\": \"Alanine-scanning mutagenesis of basic residue clusters, in vitro heparin binding assays, CXCR3 binding assays, in vitro and in vivo cell migration assays, NMR HSQC spectra\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic mutagenesis with multiple biochemical and functional assays including in vivo validation\",\n      \"pmids\": [\"20363748\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CXCL11 has potent in vivo antitumor activity mediated primarily through recruitment of CD8+CXCR3+ T lymphocytes rather than inhibition of angiogenesis; in vivo CD8+ T cell depletion completely abolished the antitumor effect, and surviving mice developed protective antitumor immunity.\",\n      \"method\": \"EL4 tumor cells genetically modified to produce murine CXCL11, in vivo tumor growth assays, flow cytometric analysis of tumor infiltrates, in vivo CD8 T cell depletion, rechallenge experiments, IFN-γ production assays, angiogenesis assessment\",\n      \"journal\": \"Journal of immunotherapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic model with depletion experiments and multiple readouts; clearly establishes CD8 T cell-dependent mechanism\",\n      \"pmids\": [\"16000952\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CXCL11/CXCR3 engagement drives an immunotolerizing state (IL-10hi Tr1 and IL-4hi Th2 cells) via p70 kinase/mTOR in STAT3- and STAT6-dependent pathways, whereas CXCL10/CXCR3 drives effector Th1 polarization via STAT1, STAT4, and STAT5. A CXCL11-Ig fusion induced remission and prevented relapse in EAE mouse model.\",\n      \"method\": \"T cell polarization assays, phospho-STAT Western blots, mTOR pathway inhibitors, CXCL11-Ig fusion protein therapeutic study in SJL/J EAE model, GFP T cell trafficking assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — distinct signaling pathways identified by multiple pharmacological and genetic approaches; functional validation in disease model; mechanistically distinguishes CXCL11 from CXCL10 signaling through same receptor\",\n      \"pmids\": [\"24713654\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CXCL11 attenuates bleomycin-induced pulmonary fibrosis by inhibiting angiogenesis and reducing pulmonary endothelial cell numbers; CXCR3 is not expressed on fibroblasts and CXCL11 has no direct effect on pulmonary fibroblasts, indicating the antifibrotic mechanism is indirect via vascular remodeling.\",\n      \"method\": \"In vivo bleomycin mouse model with systemic CXCL11 administration, collagen deposition assays, procollagen gene expression, histopathology, angiogenesis quantification, endothelial cell counting, CXCR3 expression analysis on fibroblasts\",\n      \"journal\": \"American journal of respiratory and critical care medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo model with mechanistic exclusion of direct fibroblast effects; multiple complementary readouts\",\n      \"pmids\": [\"15502109\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CXCL10 and CXCL11 are allosteric ligands of CXCR3 that engage distinct receptor conformations: CXCR3 mutants D112N, D195N, and E196Q respond to CXCL11 but not CXCL10 or synthetic agonists, indicating CXCL11 recognition by CXCR3 is largely independent of D112 and extracellular loop residues D195/E196 required for CXCL10.\",\n      \"method\": \"CXCR3 point mutant generation, radioligand binding, chemotaxis assays with natural and synthetic ligands, molecular modelling\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — mutagenesis with functional validation but single lab; molecular modelling supports interpretation\",\n      \"pmids\": [\"21895630\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ACKR3/CXCR7 binds CXCL11 through a different binding mode than CXCL12: CXCL11 requires the ACKR3 N-terminus and extracellular loop residues for primary binding and ECL residues for arrestin recruitment, while CXCL12 requires key residues D179 and D275 with no evident N-terminal involvement. Mutations reducing CXCL11 binding also impair scavenging; scavenging does not correlate with arrestin recruitment.\",\n      \"method\": \"30 ACKR3 substitution mutants, radioligand competition binding, β-arrestin recruitment assays, chemokine scavenging assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — comprehensive mutagenesis with three independent functional readouts; defines binding mode differences for two ACKR3 ligands\",\n      \"pmids\": [\"27875312\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CXCL9, CXCL10, and CXCL11 activate PI3K, MAPK, and actin reorganization in intestinal myofibroblasts through a Gαi-independent (pertussis toxin-insensitive) mechanism; CXCL11 uniquely elevates intracellular calcium in these cells despite no detectable surface CXCR3 expression, suggesting a variant or modified receptor coupling mechanism.\",\n      \"method\": \"PI3K and MAPK activation assays, actin reorganization assays, pertussis toxin treatment, calcium flux assays, CXCR3 surface expression analysis in intestinal myofibroblasts\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays in primary cell type; novel finding of Gαi-independent signaling but receptor identity unresolved\",\n      \"pmids\": [\"16210647\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CXCL11-induced CXCR3-dependent cell migration requires the membrane proximal carboxyl terminus (including the LLL motif) for internalization and migration, and the third intracellular loop S245 for integrin-dependent adhesion, actin polymerization, and migration at high CXCL11 concentrations; pertussis toxin inhibits CXCL11-induced migration confirming Gαi dependence in HEK 293 cells.\",\n      \"method\": \"CXCR3 carboxyl-terminus and third intracellular loop mutants expressed in HEK 293 cells, migration assays, internalization assays, calcium flux, integrin adhesion assays, actin polymerization assays, pertussis toxin treatment\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic receptor mutagenesis with multiple functional assays distinguishing adhesion from migration and internalization\",\n      \"pmids\": [\"16368892\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"EBV-encoded miRNA BHRF1-3 directly targets CXCL11/I-TAC mRNA; expression of BHRF1-3 inversely correlates with CXCL11 levels, and suppression of CXCL11 is reversed by transfection of antisense oligonucleotides to BHRF1-3.\",\n      \"method\": \"EBV miRNA expression profiling in primary lymphomas, inverse correlation analysis, antisense oligonucleotide rescue experiments\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — antisense rescue confirms functional targeting but full miRNA:mRNA interaction not validated by luciferase assay in this study\",\n      \"pmids\": [\"18316607\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"IFN-beta preferentially inhibits osteoclastogenesis compared to IFN-alpha2 (100-fold more potent); expression profiling identified CXCL11 as the only gene differentially upregulated by IFN-beta, and recombinant CXCL11 alone inhibits osteoclastic differentiation, indicating CXCL11 mediates part of the anti-osteoclastogenic effect of IFN-beta via autocrine signaling.\",\n      \"method\": \"Monocyte osteoclastic differentiation assays, IFN-alpha vs. IFN-beta treatment comparison, genome-wide expression profiling, recombinant CXCL11 treatment of differentiating monocytes\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — expression profiling to identify candidate, confirmed with recombinant protein functional assay; clear mechanistic link between IFN-beta signaling and CXCL11-dependent osteoclastogenesis inhibition\",\n      \"pmids\": [\"16081539\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CXCL11 promotes endometrial stromal cell proliferation via CXCR3 through p42/44 MAPK pathway activation, while inducing apoptosis of endometrial epithelial cells; IFN-gamma stimulates endometrial epithelial cells to produce CXCL11 which attracts trophoblast cells and T cells via CXCR3.\",\n      \"method\": \"Primary endometrial cell cultures, BrdU incorporation assays, lactate dehydrogenase release, annexin V staining, PD98059 MAPK inhibitor, immunoneutralization with anti-CXCL11 antibody, chemotaxis assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays with inhibitor and neutralization; cell-type-specific opposing effects established\",\n      \"pmids\": [\"17142784\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CXCL11 is secreted in a polarized basolateral-to-apical gradient by bronchial epithelial cells in COPD, driving T cell egression (transepithelial migration from interstitium to airway lumen) dependent on α4 and LFA-1 integrins, without requiring epithelial barrier disruption.\",\n      \"method\": \"Transepithelial resistance measurements, T cell migration assays across intact bronchial epithelium, integrin-blocking antibodies, CXCL11 localization by immunofluorescence, COPD patient biopsies\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional migration assays with specific integrin blockade and directional gradient established; polarized CXCL11 shown in patient tissue\",\n      \"pmids\": [\"18209084\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CXCL11 (IP-9/I-TAC) produced by re-differentiating keratinocytes is required for wound repair: mice with antisense-mediated elimination of IP-9 expression during wound healing exhibit delayed re-epithelialization, hypercellular immature dermis, persistent provisional matrix components, and severely diminished basement membrane components (laminin V and collagen IV) without altered inflammatory response.\",\n      \"method\": \"Antisense transgenic mouse model (IP-9AS), full and partial thickness excisional wounds, histological analysis over 2 months, immunohistochemistry for matrix components\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo loss-of-function genetic model with multiple tissue-level readouts; establishes specific role of CXCL11 in wound maturation\",\n      \"pmids\": [\"18669615\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Docetaxel induces ROS-dependent HMGB1 release from tumor cells; HMGB1 then stimulates CXCL11 secretion via NF-κB activation, and CXCL11 enhances CD8+ T cell recruitment to the tumor microenvironment through CXCR3.\",\n      \"method\": \"Flow cytometry, immunofluorescence, Western blotting for HMGB1 and CXCL11, recombinant HMGB1 stimulation of CXCL11 production, ROS inhibition, NF-κB pathway analysis, in vivo CAR T cell recruitment assays\",\n      \"journal\": \"Journal for immunotherapy of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway established with multiple orthogonal methods in vitro and in vivo; identifies HMGB1-NF-κB-CXCL11 axis\",\n      \"pmids\": [\"30744691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"STAT2 regulates CXCL11 expression specifically in response to IFNα in keratinocytes; siRNA knockdown of STAT2 reduces IFNα-induced CXCL11 and CCL5 expression among 102 cytokines tested. This STAT2-dependent regulation of CXCL11 also requires IRF9 but not STAT1 or STAT6.\",\n      \"method\": \"STAT2 siRNA knockdown in human keratinocytes, 102-cytokine multiplex analysis, IFNα stimulation, IRF9/STAT1/STAT6 knockdown experiments\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gene-specific knockdown with broad cytokine screen identifying CXCL11 as selectively regulated; IRF9 dependence confirmed\",\n      \"pmids\": [\"28472186\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"RBM15 enhances CXCL11 mRNA stability in an m6A-dependent manner in ccRCC cells; elevated RBM15 (driven by EP300/CBP-mediated histone acetylation of its promoter) increases CXCL11 secretion, which promotes macrophage infiltration and M2 polarization.\",\n      \"method\": \"RBM15 knockdown/overexpression, CXCL11 mRNA stability assays, m6A modification assays, ChIP for H3 acetylation, macrophage co-culture, in vivo xenograft models\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — m6A-dependent mRNA stability mechanism supported by multiple molecular and functional assays\",\n      \"pmids\": [\"35381326\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Estrogen receptor α (ERα) directly binds the CXCR7 promoter in ovarian cancer cells to upregulate CXCR7 expression in response to estrogen; CXCL11 is also upregulated by estrogen, and CXCL11-induced ERα Ser-118 phosphorylation creates a positive feedback loop reinforcing CXCR7 transcription. CXCR7 (not CXCR3) mediates estrogen-induced mesenchymal marker expression and cancer cell migration.\",\n      \"method\": \"ChIP for ERα at CXCR7 promoter, histone modification analysis, CXCR7 siRNA knockdown, CXCL11-dependent ERα phosphorylation assays, cell migration assays, laser-capture microdissection of clinical samples\",\n      \"journal\": \"Molecular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP, phosphorylation assays, and functional rescue establish feedback mechanism; validated in clinical specimens\",\n      \"pmids\": [\"30051594\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The CXCR3-CXCL11 signaling axis mediates macrophage chemotaxis to bacterial infection sites in zebrafish; loss of the zebrafish CXCR3 ortholog (cxcr3.2) attenuates macrophage recruitment to infection foci, reduces granuloma formation, limits mycobacterial dissemination, and decreases bacterial burden. Recombinant CXCL11-like chemokines exert Cxcr3.2-dependent chemoattraction in vivo.\",\n      \"method\": \"Zebrafish cxcr3.2 mutant analysis, NBI74330 CXCR3 antagonist treatment, in vivo injection of recombinant CXCL11-like proteins, M. marinum infection model, macrophage migration imaging, granuloma quantification\",\n      \"journal\": \"Disease models & mechanisms\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic and pharmacological loss-of-function with receptor-specific rescue; conserved function validated across vertebrates\",\n      \"pmids\": [\"25573892\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"IL-18 enhances IFN-γ-induced CXCL9, CXCL10, and CXCL11 production in human keratinocytes by activating NF-κB, STAT1, and IRF-1 through PI3K/Akt and MEK/ERK pathways; antisense oligonucleotides against NF-κB p50, p65, or STAT1 suppress CXCL11 production, and antisense IRF-1 specifically suppresses CXCL11.\",\n      \"method\": \"Cytokine stimulation of primary keratinocytes, ELISA, antisense oligonucleotides against transcription factors, PI3K/p38 MAPK/MEK inhibitors, phosphorylation assays\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — antisense knockdown and inhibitor studies identify transcription factors required for CXCL11; IRF-1 specifically required for CXCL11 vs. CXCL9/10\",\n      \"pmids\": [\"17274000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CXCL11 promotes self-renewal, tumorigenic, and chemoresistance properties of α2δ1+ hepatocellular carcinoma tumor-initiating cells via ERK1/2 activation through CXCR3 in an autocrine manner, inducing stem cell-related genes BMI1, NANOG, MDR1, ABCG2, and CACNA2D1.\",\n      \"method\": \"CXCL11 stimulation of α2δ1+ HCC TICs, sphere formation assays, tumor initiation assays, ERK1/2 phosphorylation assays, CXCR3 receptor blocking, gene expression profiling of stemness markers\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — CXCR3 blocking and ERK1/2 pathway inhibition establish receptor-pathway linkage with functional readouts\",\n      \"pmids\": [\"30771435\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CXCL11 is an IFN-γ-inducible non-ELR CXC chemokine that primarily signals through CXCR3 (with higher affinity than CXCL9/CXCL10), activating Gαi-dependent calcium flux, ERK1/2, PI3K, and mTOR/STAT3 pathways to drive T cell chemotaxis, keratinocyte migration via mu-calpain, and context-dependent immunotolerizing Tr1/Th2 polarization; it also binds CXCR7/ACKR3 as a scavenged decoy ligand and acts as a natural antagonist at CCR3 and CCR5; its activity is regulated post-translationally by DPP IV-mediated N-terminal cleavage (inactivation), MMP processing (conversion to CXCR3 antagonist), PAD-mediated citrullination (reduced signaling), glycosaminoglycan binding via C-terminal helix residues (required for in vivo gradient formation), and transcriptionally by TYK2-dependent IFN signaling, STAT2/IRF9, STAT3, NF-κB p65 Arg174 methylation by PRMT5, and miR-34a-5p/miR-206-mediated 3'UTR repression.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CXCL11 is an interferon-inducible, non-ELR CXC chemokine that functions as the highest-affinity ligand for CXCR3, driving chemotaxis of activated T cells, macrophages, and keratinocytes while also acting as a natural antagonist at CCR3 and CCR5 and serving as a scavenged ligand for the decoy receptor CACKR3/CXCR7 [PMID:9625760, PMID:11110785, PMID:15178708, PMID:16940167]. Signaling through CXCR3 activates Gαi-dependent calcium flux, PLC-β3/μ-calpain-mediated focal adhesion disassembly in keratinocytes, ERK1/2-driven proliferation and stemness programs, and an mTOR/STAT3/STAT6-dependent immunotolerizing pathway that polarizes T cells toward Tr1/Th2 fates — distinguishing CXCL11 from the Th1-promoting ligand CXCL10 despite sharing the same receptor [PMID:15713646, PMID:24713654, PMID:30771435]. CXCL11 activity is tightly regulated post-translationally: DPP IV N-terminal cleavage abolishes agonism, MMP-mediated truncation converts it to a CXCR3 antagonist, citrullination by PAD impairs signaling, and C-terminal helix residues mediating glycosaminoglycan binding are required for in vivo gradient formation and leukocyte recruitment [PMID:12101279, PMID:18411283, PMID:18645041, PMID:20363748]. Transcriptional induction requires TYK2 kinase activity, a non-canonical unphosphorylated STAT3 scaffold that recruits NF-κB p65 and IRF1 to the promoter, STAT2/IRF9 in response to IFNα, and PRMT5-dependent symmetric dimethylation of p65 Arg174 [PMID:9890942, PMID:17202361, PMID:28472186, PMID:26901772].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Establishing that CXCL11 is a CXCR3-selective chemokine with the highest receptor affinity among its family members resolved the identity and primary receptor for this IFN-inducible chemokine and defined its cellular target as activated T cells.\",\n      \"evidence\": \"Receptor binding assays, calcium flux, and chemotaxis in IL-2-activated T cells and CXCR3 transfectants\",\n      \"pmids\": [\"9625760\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream intracellular signaling cascades not yet mapped\", \"In vivo relevance of CXCR3 selectivity untested\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Demonstrating that CXCL11 induction requires catalytically active TYK2 beyond the canonical ISGF3 pathway established that CXCL11 transcription depends on a specialized IFN signaling branch distinct from typical ISGs.\",\n      \"evidence\": \"TYK2-deficient cell complementation with kinase-dead mutants and promoter-reporter assays\",\n      \"pmids\": [\"9890942\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream TYK2 substrates specific to CXCL11 induction not identified\", \"Whether TYK2 requirement extends to IFN-γ vs. IFN-β not resolved\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Revealing that CXCL11 acts as a natural antagonist of CCR3 expanded its functional repertoire beyond CXCR3 agonism to include counter-regulation of eosinophil chemotaxis, providing a mechanism for cross-talk between Th1 and Th2 chemokine systems.\",\n      \"evidence\": \"Competitive binding, calcium flux, and chemotaxis assays with CCR3 transfectants and human eosinophils\",\n      \"pmids\": [\"11110785\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of CCR3 antagonism vs. CXCR3 agonism unknown\", \"In vivo relevance of CCR3 antagonism not tested\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identifying DPP IV-mediated N-terminal cleavage as an inactivation mechanism established the first post-translational regulatory switch for CXCL11 and showed the truncated product acts as a desensitizing agent.\",\n      \"evidence\": \"Mass spectrometry of cleavage product, calcium flux and chemotaxis assays with T cells\",\n      \"pmids\": [\"12101279\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of DPP IV cleavage vs. other proteases in vivo unclear\", \"Whether truncated CXCL11(3-73) has physiological antagonist function in tissues untested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showing that CXCL11 activates CXCR3-B to mediate angiostatic effects on endothelial cells revealed that receptor splice variant usage determines whether CXCL11 promotes migration or inhibits proliferation/induces apoptosis.\",\n      \"evidence\": \"HMEC-1 transfection with CXCR3-A or CXCR3-B, radioligand binding, DNA synthesis, apoptosis assays\",\n      \"pmids\": [\"12782716\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative expression levels of CXCR3-A vs. CXCR3-B across tissues not systematically mapped\", \"Signaling pathways downstream of CXCR3-B not fully delineated\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Mapping the intracellular domains of CXCR3 required for CXCL11 vs. CXCL10/CXCL9 responses demonstrated biased agonism at the receptor level — CXCL11 uniquely requires the third intracellular loop for internalization while other ligands require the C-terminus and β-arrestin1, and CXCL11 also antagonizes CCR5 via specific surface residues.\",\n      \"evidence\": \"CXCR3 deletion/point mutants with internalization, chemotaxis, and calcium assays; CCR5 competitive binding and structure-activity analysis\",\n      \"pmids\": [\"15150261\", \"15178708\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether biased signaling translates to distinct gene expression programs in T cells unknown\", \"Crystal structure of CXCL11-CXCR3 complex unavailable\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Solving the NMR structure of CXCL11 revealed a monomeric chemokine with a beta-bulge preventing dimerization, providing a structural explanation for its distinct receptor binding properties.\",\n      \"evidence\": \"Solution NMR structure determination\",\n      \"pmids\": [\"15273303\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No CXCL11-receptor complex structure\", \"Functional significance of obligate monomerism vs. other CXCR3 ligands unexplored\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Multiple 2005 studies established diverse biological outputs: CXCL11 promotes keratinocyte wound healing via PLC-β3/μ-calpain/FAK cleavage, drives CD8+ T cell-dependent antitumor immunity in vivo, inhibits osteoclastogenesis downstream of IFN-β, and is required for wound maturation in vivo.\",\n      \"evidence\": \"RNAi distinguishing calpain isoforms in keratinocytes; EL4 tumor model with CD8 depletion; monocyte osteoclast differentiation assays; antisense transgenic wound model\",\n      \"pmids\": [\"15713646\", \"16000952\", \"16081539\", \"18669615\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether μ-calpain pathway operates in non-keratinocyte CXCR3+ cells unknown\", \"Relative contribution of CXCL11 vs. CXCL9/10 to CD8 T cell tumor recruitment not dissected\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identifying CXCR7 as a high-affinity alternate receptor for CXCL11 that does not couple to G-proteins but promotes cell survival and adhesion revealed a second receptor system operating as a ligand sink.\",\n      \"evidence\": \"Radioligand binding, calcium and migration assays (negative), adhesion and tumor growth assays in vivo\",\n      \"pmids\": [\"16940167\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling pathways downstream of CXCR7 upon CXCL11 binding not identified\", \"Relative contribution of CXCR7 scavenging to CXCL11 gradient shaping in vivo unclear\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstrating that STAT3 (independent of Y705 phosphorylation) scaffolds NF-κB p65 and IRF1 onto the CXCL11 promoter while its absence permits repressor binding resolved the non-canonical transcription factor requirement for CXCL11 induction.\",\n      \"evidence\": \"STAT3-deficient cells with WT/Y705F reconstitution, ChIP at CXCL11 promoter, promoter-reporter assays\",\n      \"pmids\": [\"17202361\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct protein-protein interaction between unphosphorylated STAT3, p65, and IRF1 not biochemically reconstituted\", \"Whether this non-canonical STAT3 mechanism operates in all CXCL11-producing cell types untested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Characterizing MMP-mediated proteolytic processing and PAD-mediated citrullination as two additional post-translational regulatory mechanisms showed that CXCL11 can be converted from agonist to antagonist (by MMPs) or functionally attenuated (by citrullination), with C-terminal truncation ablating both receptor and GAG binding.\",\n      \"evidence\": \"MALDI-TOF MS of MMP cleavage products with chemotaxis/heparin binding; PAD citrullination with MS and functional assays\",\n      \"pmids\": [\"18411283\", \"18645041\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo prevalence of citrullinated vs. MMP-truncated CXCL11 forms unknown\", \"Which MMP family members are most relevant in specific tissue contexts not established\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Mapping the GAG-binding epitope to C-terminal helix residues K57-K58-R62 and K17 and showing that GAG-binding mutants fail in vivo despite normal in vitro chemotaxis established that heparan sulfate immobilization is essential for CXCL11 gradient function in tissues; separately, CXCR7 was confirmed as a constitutively cycling scavenger that internalizes and degrades CXCL11.\",\n      \"evidence\": \"Alanine-scanning mutagenesis with in vitro/in vivo migration assays; live-cell imaging of CXCR7 cycling and ligand degradation in mammalian cells and zebrafish\",\n      \"pmids\": [\"20363748\", \"20161793\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific GAG composition effects on CXCL11 gradient formation unknown\", \"Relative quantitative contribution of CXCR7 vs. DPP IV/MMPs to CXCL11 clearance in vivo not determined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrating that CXCL11 and CXCL10 activate distinct signaling cascades through the same receptor — CXCL11 driving mTOR/STAT3/STAT6-dependent Tr1/Th2 tolerance vs. CXCL10 driving STAT1/4/5-dependent Th1 immunity — resolved a long-standing puzzle of how three ligands sharing one receptor produce opposing immunological outcomes.\",\n      \"evidence\": \"T cell polarization, phospho-STAT blots, mTOR inhibitors, CXCL11-Ig fusion therapeutic in EAE model\",\n      \"pmids\": [\"24713654\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for biased agonism at CXCR3 not determined\", \"Whether tolerance-inducing pathway operates in all T cell subsets or disease contexts unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identifying PRMT5-mediated Arg174 dimethylation of NF-κB p65 as required for p65 association with the CXCL11 promoter added an epigenetic regulatory layer to CXCL11 transcription; separately, systematic ACKR3 mutagenesis revealed a CXCL11 binding mode distinct from CXCL12, with scavenging decoupled from arrestin recruitment.\",\n      \"evidence\": \"PRMT5 RNAi, p65 R174 mutant reconstitution, ChIP/Re-ChIP; 30 ACKR3 substitution mutants with binding, arrestin, and scavenging assays\",\n      \"pmids\": [\"26901772\", \"27875312\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PRMT5-p65 methylation is a general NF-κB target gene mechanism or CXCL11-selective unclear\", \"ACKR3-mediated signaling events independent of G-proteins and arrestins not identified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Establishing STAT2/IRF9 (but not STAT1) as required for IFNα-induced CXCL11 expression in keratinocytes identified a cell-type-specific transcriptional input distinct from the STAT3/IRF1 axis described in other contexts.\",\n      \"evidence\": \"STAT2 siRNA in keratinocytes, 102-cytokine multiplex screen, IRF9/STAT1/STAT6 knockdowns\",\n      \"pmids\": [\"28472186\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether STAT2/IRF9 and STAT3/IRF1 pathways converge or operate in distinct cell types not resolved\", \"Promoter occupancy by STAT2/IRF9 not demonstrated by ChIP in this study\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Two studies extended CXCL11 biology to tumor microenvironment signaling: docetaxel-induced HMGB1 stimulates CXCL11 via NF-κB to recruit CD8+ T cells, while autocrine CXCL11/CXCR3/ERK1/2 signaling maintains stemness in hepatocellular carcinoma tumor-initiating cells.\",\n      \"evidence\": \"HMGB1-NF-κB-CXCL11 pathway analysis with ROS inhibition and in vivo CAR T recruitment; CXCR3 blocking and ERK inhibition in HCC sphere assays\",\n      \"pmids\": [\"30744691\", \"30771435\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether CXCL11-driven stemness operates in tumor types beyond HCC untested\", \"Relative importance of CXCL11 vs. CXCL9/10 in docetaxel-induced immune recruitment not quantified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showing that RBM15 stabilizes CXCL11 mRNA via m6A modification to promote macrophage infiltration and M2 polarization in ccRCC introduced epitranscriptomic regulation as a mechanism controlling CXCL11 abundance.\",\n      \"evidence\": \"RBM15 knockdown/overexpression, m6A assays, mRNA stability measurements, macrophage co-culture, xenograft models\",\n      \"pmids\": [\"35381326\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific m6A sites on CXCL11 mRNA not mapped\", \"Whether m6A-dependent regulation operates outside ccRCC unclear\", \"Reader proteins mediating m6A-dependent CXCL11 stability not identified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of biased agonism at CXCR3 (no CXCL11-CXCR3 complex structure exists), the in vivo quantitative hierarchy among the multiple post-translational regulatory mechanisms (DPP IV, MMPs, PAD, CXCR7 scavenging), and whether CXCL11's immunotolerizing signaling can be therapeutically harnessed independently of its chemotactic function.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No atomic-resolution CXCL11-CXCR3 complex structure\", \"Quantitative in vivo contribution of each proteolytic/PTM pathway to CXCL11 regulation not established\", \"Therapeutic separation of tolerogenic vs. chemotactic functions not achieved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 2, 9, 11, 16, 17]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [2, 9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 26, 27, 28]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 16, 17, 28, 32]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 11, 17, 22, 34]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CXCR3\",\n      \"ACKR3\",\n      \"CCR3\",\n      \"CCR5\",\n      \"DPP4\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}